Toripalimab (JS001 ) Lenvatinib

PreclinicalSmall molecule

Toripalimab (JS001 ) Lenvatinib is one of 5 small molecule programs targeting Minimal Residual Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Minimal Residual DiseaseNot yet recruiting

Minimal Residual DiseasePreclinical

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Minimal Residual Disease

#DrugCompanyPhaseTrials

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

1 2

Beyfortus

BeiGene

Phase 2

1 3

Elunate

Takeda

Phase 2

1 4

Besponsa

WWyeth-Lederle Vaccines

Phase 2

1 5

Toripalimab (JS001 ) Lenvatinib

SShanghai Junshi Bioscience Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

N/ANot yet recruiting

Minimal Residual Disease

NCT06709274

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT03581786·289 enrolled

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT03856411·465 enrolled

Minimal Residual Disease1 trial

Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

Not yet recruiting·GGuangdong Association of Clinical Trials·N/A·NCT06709274·342 enrolled

Hepatocellular Carcinoma1 trial

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Terminated·SShanghai Junshi Bioscience Co., Ltd.·Phase 1/2·NCT03867370·40 enrolled

Nasopharyngeal Carcinoma1 trial

A Randomised, Open-label, Phase I Dose Exploration Study to Compare Single, Multiple, and Long-term Dosing of Toripalimab Injection (Subcutaneous) With Toripalimab Injection (IV) in Patients With Advanced Nasopharyngeal Carcinoma

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT05751486·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Toripalimab (JS001 ) Lenvatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Toripalimab (JS001 ) Lenvatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Toripalimab (JS001 ) Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Junshi Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Junshi Bioscience Co., Ltd.

Toripalimab (JS001 ) Lenvatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Efficacy and Safety2 trials

Minimal Residual Disease1 trial

Hepatocellular Carcinoma1 trial

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News